[Correlation analysis of Poor Prognosis and Immunotherapy of lncRNAs Related with m 6A Modification in Cervical Cancer].

• DOI: 10.12182/20220760504
• Publication Date: 2022-07-01
• Authors: Rui Gu; Min Liu; Ping Lin; Tianyu Feng; Hang Yuan; Deqiong Ou; Siqi Li; Qin Li; Gang Zhao; Jie Zhang; Kai Li

To study the correlation between N 6-methyladenosine (m 6A)-modification-associated long non-coding RNAs (lncRNAs) and poor prognosis immunotherapy in cervical cancer based on data mining of The Cancer Genome Atlas (TCGA) dataset, so as to assess effectively patients feasibility immunotherapy.We identified m 6A-modification-associated lncRNAs correlated by conducting bioinformatics analysis samples from TCGA datasets constructed a prognostic risk model accordingly.A total 343 were 304 patients. Univariate Cox regression showed that 26 out significantly associated with We 7 lncRNAs, including DLEU1, AC099850.4, DDN-AS1, EP300-AS1, AC131159.1, AL441992.2, AL021707.6 through Lasso then developed them. According Kaplan-Meier survival analysis, low-risk group exhibited improved overall (OS) comparison those high-risk ( P<0.001). area under curve AUC) receiver operating characteristic (ROC) demonstrated high sensitivity credibility model. Multivariate score was an independent factor Tumor immune dysfunction exclusion (TIDE) predicted would benefit more immunotherapy. In addition, we found checkpoint PD1 expression m6A-modification-related such higher P<0.05).The basis aforementioned can be used predict efficacy targeting PD1.